The first 10 months by the CDE priority review of 40 enterprises involving Hengrui, Junshi, stone medicine:

Statistics in the first ten months of 2020 by the State Drug Administration priority review of enterprises, a total of 40 enterprises 48 products to obtain priority review qualifications, 30 domestic pharmaceutical enterprises (75%) a total of 34 products (70.8%) to obtain priority review qualifications, including Hengrui, Howson, Shi Pharmaceuticals, first sound, Baiji Shenzhou, Junshi biological, and then Ding medicine, among which Hengrui, Baiji Shenzhou, respectively, 3 products to obtain priority review qualifications, Keystone Pharmaceuticals, Foshan Deyi Can Pharmaceuticals have 2 products to obtain priority review qualifications, the rest of the domestic enterprises have 1 product to obtain priority review qualifications.
details of the priority review of biopharmaceons and Class 1 chemicals for domestic enterprises, as shown in the table below.
11 chemical generics were given priority review, as detailed in the table below.
foreign enterprises, Roche 5 products were qualified for priority review, worthy of the global king of innovative drugs.
In addition, Bayer's two products were eligible for priority review, and one of the seven companies, Sanofi, AstraZenetel, Astellas, Mercedon, Xi'an Jansen, Concorde Kirin and GlaxoSmithKline, was eligible for priority review.
priority review of foreign enterprises is shown in the table below.